The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence

被引:59
作者
Xiang, Yu-zhu [1 ]
Xiong, Hui [1 ]
Cui, Zi-lian [1 ]
Jiang, Shao-bo [1 ]
Xia, Qing-hua [1 ]
Zhao, Yong [1 ]
Li, Guan-bin [1 ]
Jin, Xun-bo [1 ]
机构
[1] Shandong Univ, Prov Hosp, Minimally Invas Urol Ctr, Jinan 250021, Peoples R China
关键词
Gleason score; Recurrence; Clinical stage; Aggressiveness; COHORT; IMPACT; MEN;
D O I
10.1186/1756-9966-32-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although a previous meta-analysis reported no association between metabolic syndrome (MetS) and prostate cancer risk, a number of studies suggest that MetS may be associated with the aggressiveness and progression of prostate cancer. However, these results have been inconsistent. This systematic review and meta-analysis investigated the nature of this association. Methods: We systematically searched MEDLINE, EMBASE and bibliographies of retrieved studies up to January 2013 using the keywords "metabolic syndrome" and "prostate cancer". We assessed relative risks (RRs) of the prostate cancer, several parameters of prostate cancer aggressiveness and progression associated with MetS using 95% confidence intervals (95% CIs). Results: The literature search produced 547 hits from which 19 papers were extracted for the meta-analysis. In cancer-free population with and without MetS, the combined adjusted RR (95% CI) of prostate cancer risk and prostate cancer-specific mortality in longitudinal cohort studies is 0.96 (0.85 similar to 1.09) and 1.12 (1.02 similar to 1.23) respectively. In the prostate cancer patients with and without MetS, the combined unadjusted OR (95% CI) of high grade Gleason prostate cancer is 1.44 (1.20 similar to 1.72), the OR of advanced prostate cancer is 1.37 (1.12 similar to 1.68) and the OR of biochemical recurrence is 2.06 (1.43 similar to 2.96). Conclusions: The overall analyses revealed no association between MetS and prostate cancer risk, although men with MetS appear more likely to have high-grade prostate cancer and more advanced disease, were at greater risk of progression after radical prostatectomy and were more likely to suffer prostate cancer-specific death. Further primary studies with adjustment for appropriate confounders and larger, prospective, multicenter investigations are required.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence
    Yu-zhu Xiang
    Hui Xiong
    Zi-lian Cui
    Shao-bo Jiang
    Qing-hua Xia
    Yong Zhao
    Guan-bin Li
    Xun-bo Jin
    Journal of Experimental & Clinical Cancer Research, 32
  • [2] The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma
    Wang, Jun
    Abudurexiti, Mierxiati
    Shao, Ning
    Wei, Yu
    Zhu, Yao
    Ye, Ding-wei
    EUROPEAN UROLOGY FOCUS, 2020, 6 (01): : 53 - 62
  • [3] Antioxidant and Vitamin E Transport Genes and Risk of High-Grade Prostate Cancer and Prostate Cancer Recurrence
    Bauer, Scott R.
    Richman, Erin L.
    Sosa, Eduardo
    Weinberg, Vivian
    Song, Xiaoling
    Witte, John S.
    Carroll, Peter R.
    Chan, June M.
    PROSTATE, 2013, 73 (16) : 1786 - 1795
  • [4] Assessment of high-grade prostate cancer risk using prostate cancer biomarkers
    Stanton, Whitney N.
    Crawford, E. David
    Arangua, Paul B.
    La Rosa, Francisco G.
    van Bokhoven, Adrie
    Lucia, M. Scott
    Poage, Wendy L.
    Partin, Alan
    Maroni, Paul
    Werahera, Priya N.
    CANADIAN JOURNAL OF UROLOGY, 2020, 27 (01) : 10080 - 10085
  • [5] Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer
    Mahal, Brandon A.
    Aizer, Ayal A.
    Efstathiou, Jason A.
    Nguyen, Paul L.
    CANCER, 2016, 122 (01) : 78 - 83
  • [6] Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study
    Freedland, S. J.
    Hamilton, R. J.
    Gerber, L.
    Banez, L. L.
    Moreira, D. M.
    Andriole, G. L.
    Rittmaster, R. S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (03) : 254 - 259
  • [7] Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer
    Mahal, Brandon A.
    Yang, David D.
    Wang, Natalie Q.
    Alshalalfa, Mohammed
    Davicioni, Elai
    Choeurng, Voleak
    Schaeffer, Edward M.
    Ross, Ashley E.
    Spratt, Daniel E.
    Den, Robert B.
    Martin, Neil E.
    Mouw, Kent W.
    Orio, Peter F., III
    Choueiri, Toni K.
    Taplin, Mary-Ellen
    Quoc-Dien Trinh
    Feng, Felix Y.
    Nguyen, Paul L.
    EUROPEAN UROLOGY, 2018, 74 (02) : 146 - 154
  • [8] Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations
    Van den Broeck, Thomas
    van den Bergh, Roderick C. N.
    Briers, Erik
    Cornford, Philip
    Cumberbatch, Marcus
    Tilki, Derya
    De Santis, Maria
    Fanti, Stefano
    Fossati, Nicola
    Gillessen, Silke
    Grummet, Jeremy P.
    Henry, Ann M.
    Lardas, Michael
    Liew, Matthew
    Mason, Malcolm
    Moris, Lisa
    Schoots, Ivo G.
    van der Kwast, Theodorus
    van der Poel, Henk
    Wiegel, Thomas
    Willemse, Peter-Paul M.
    Rouviere, Olivier
    Lam, Thomas B.
    Mottet, Nicolas
    EUROPEAN UROLOGY FOCUS, 2020, 6 (02): : 231 - 234
  • [9] Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study
    Song, Pan
    Yang, Bo
    Peng, Zhufeng
    Zhou, Jing
    Ren, Zhengju
    Fang, Kun
    Yang, Luchen
    Wang, Linchuan
    Dong, Qiang
    INTERNATIONAL JOURNAL OF SURGERY, 2020, 76 : 64 - 68
  • [10] Association between metabolic syndrome, diabetes mellitus and prostate cancer risk
    Lawrence, Y. R.
    Morag, O.
    Benderly, M.
    Boyko, V.
    Novikov, I.
    Dicker, A. P.
    Goldbourt, U.
    Behar, S.
    Barchana, M.
    Wolf, I.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (02) : 181 - 186